@Article{Graczyk2023,
journal="Medycyna Paliatywna/Palliative Medicine",
issn="2081-0016",
volume="15",
number="2",
year="2023",
title="Is there a place for cannabigerol in symptomatic treatment?",
abstract="Cannabigerol (CBG) is one of the compounds derived from Cannabis sativa L. that has drawn researchers’ attention in recent years. In the process of biosynthesis, CBG acts as a precursor to various phytocannabinoids, including cannabidiol (CBD) and Δ9-tetrahydrocannabinol. After administration into the human body, however, it does not result in the formation of other cannabinoids due to the lack of necessary conversion pathways. Cannabigerol acts on serotonergic, α2 adrenergic receptors, peroxisome proliferator-activated receptors, and the cannabinoid receptor family. In addition, it presents an inhibitory effect on several anti-inflammatory mediators. Despite its weak interaction with CB1 and CB2 cannabinoid receptors, among phytocannabinoids it is the most potent ligand of the transient receptor vanilloid potential 1. When the endocannabinoid system becomes disrupted in various disease states, CBG, through its potential effects, can have an impact on maintaining homeostasis in the body. The range of its biological activity includes anti-inflammatory, antibacterial, antifungal, and neuromodulatory properties, as well as the regulation of redox balance. Applications for CBG have already been found in astrointestinal, metabolic, and neurological disorders, as well as numerous inflammatory diseases. We are currently witnessing a widespread increase in the use of CBG in medicine due to its beneficial effects on health while lacking psychoactivity. Despite the growing interest, caution should be exercised in the use of CBG and CBD due to possible interactions with other medications.",
author="Graczyk, Michał
and Pawlak, Łukasz
and Lewandowska, Agata",
pages="50--58",
doi="10.5114/pm.2023.131449",
url="http://dx.doi.org/10.5114/pm.2023.131449"
}